In a recent statement, the FDA said they are “evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics."
The FDA review is prompted by both new evidence and older reports of adverse events linked with the drugs. In February 2013, researchers at Johns Hopkins published a study in JAMA Internal Medicine, (2/25/13), that showed people taking Byetta, Bydureon or Januvia had double the rate of acute pancreatitis.
READ MORE Januvia LEGAL NEWS
The JAMA study found that patients hospitalized with pancreatitis were two times more likely to be taking either Januvia or Byetta than diabetic patients who did not have pancreatitis. The study concerned Consumer Reports (3/5/13) enough that it issued an article warning patients to talk to their doctor about switching to another medication.